Potency Assay Development and Validation
The Pharmaron US team has a proven track record of successfully supporting cell and gene therapy (CGT) programs from preclinical to post market approval. To date, Pharmaron is the only CRO in the United States who has validated a potency assay for an FDA-approved gene therapy product, and we continue to support the batch release testing of this product. Potency is a critical quality attribute (CQA) of any CGT product and a prerequisite for biological license application (BLA) approval and for the release of manufactured lots.
View as PDF: Potency Assay Development and Validation
Download Whitepaper: Potency Assay Development for Cell and Gene Therapy
Download E-book: Potency Assay Guide
Services
- Top-Down Approach for the Ideal Assay Profile™ (IAP) leverages any combination (but not limited to): enzyme activity, transporter, transcription factor activation, receptor-mediated signaling pathways, intracellular protein-protein interactions, and more
- Full support of potency assays from development, optimization, qualification, validation to GMP lot release, including the generation and maintenance of cGMP master cell banks
- A reliable, experienced and knowledgeable partner with a breadth of models (in vivo, ex vivo, and in vitro), analytical techniques, redundancy in equipment, trained analysts, compliant facilities, and quality systems
- Assay development adheres closely to guidelines from governing agencies (e.g. USP, ICH, GMP, FDA, EMA)
Capabilities
- Technology Platforms: HPLC, LC-MS/MS, qPCR/ddPCR, ligand binding assays (ELISA), flow cytometry, high-content imaging, western blot
Learn more about Pharmaron’s expertise by registering for our monthly CGT webinar series, which is focused on identifying key cell and gene therapy questions that arise during drug discovery and development. Register here.
